News | February 24, 2026
Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
Under the deal, Quiver will receive an undisclosed advance payment and research support
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
If approved, DTX401 would be the first treatment to address the disease at its root cause
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
